Tags

Type your tag names separated by a space and hit enter

Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Ann Rheum Dis. 2020 09; 79(9):1170-1173.AR

Abstract

BACKGROUND

The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.

METHODS

We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups.

RESULTS

Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution.

CONCLUSION

Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.

Authors+Show Affiliations

Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain jlpablos@h12o.es. Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain.Servicio de Reumatologia, Hospital Clínico San Carlos, Instituto Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain.Servicio de Reumatologia, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain. Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidad de A Coruña, A Coruña, Spain.Servicio de Reumatologia, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander, Cantabria, Spain.Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain.Servicio de Reumatologia, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.Servicio de Reumatologia, Hospital Clínico San Carlos, Instituto Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain.Servicio de Reumatologia, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander, Cantabria, Spain.Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. UGC de Reumatología, Hospital Regional Universitario de Málaga, Malaga, Andalucía, Spain.Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. UGC de Reumatología, Hospital Regional Universitario de Málaga, Malaga, Andalucía, Spain.Servicio de Reumatologia, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.Servicio de Reumatologia, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32532753

Citation

Pablos, Jose L., et al. "Prevalence of Hospital PCR-confirmed COVID-19 Cases in Patients With Chronic Inflammatory and Autoimmune Rheumatic Diseases." Annals of the Rheumatic Diseases, vol. 79, no. 9, 2020, pp. 1170-1173.
Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170-1173.
Pablos, J. L., Abasolo, L., Alvaro-Gracia, J. M., Blanco, F. J., Blanco, R., Castrejón, I., Fernandez-Fernandez, D., Fernandez-Gutierrez, B., Galindo-Izquierdo, M., Gonzalez-Gay, M. A., Manrique-Arija, S., Mena Vázquez, N., Mera Varela, A., Retuerto, M., & Seijas-Lopez, A. (2020). Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 79(9), 1170-1173. https://doi.org/10.1136/annrheumdis-2020-217763
Pablos JL, et al. Prevalence of Hospital PCR-confirmed COVID-19 Cases in Patients With Chronic Inflammatory and Autoimmune Rheumatic Diseases. Ann Rheum Dis. 2020;79(9):1170-1173. PubMed PMID: 32532753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. AU - Pablos,Jose L, AU - Abasolo,Lydia, AU - Alvaro-Gracia,Jose M, AU - Blanco,Francisco J, AU - Blanco,Ricardo, AU - Castrejón,Isabel, AU - Fernandez-Fernandez,David, AU - Fernandez-Gutierrez,Benjamín, AU - Galindo-Izquierdo,María, AU - Gonzalez-Gay,Miguel A, AU - Manrique-Arija,Sara, AU - Mena Vázquez,Natalia, AU - Mera Varela,Antonio, AU - Retuerto,Miriam, AU - Seijas-Lopez,Alvaro, AU - ,, Y1 - 2020/06/12/ PY - 2020/04/27/received PY - 2020/05/28/revised PY - 2020/05/28/accepted PY - 2020/6/14/pubmed PY - 2020/9/9/medline PY - 2020/6/14/entrez KW - arthritis KW - autoimmune diseases KW - biological therapy KW - epidemiology SP - 1170 EP - 1173 JF - Annals of the rheumatic diseases JO - Ann Rheum Dis VL - 79 IS - 9 N2 - BACKGROUND: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. METHODS: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups. RESULTS: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution. CONCLUSION: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/32532753/Prevalence_of_hospital_PCR_confirmed_COVID_19_cases_in_patients_with_chronic_inflammatory_and_autoimmune_rheumatic_diseases_ L2 - https://ard.bmj.com/lookup/pmidlookup?view=long&pmid=32532753 DB - PRIME DP - Unbound Medicine ER -